<DOC>
	<DOCNO>NCT02087943</DOCNO>
	<brief_summary>A study evaluate efficacy safety apremilast ( CC-10004 ) subject moderate severe atopic dermatitis</brief_summary>
	<brief_title>Efficacy Safety Study Apremilast Subjects With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Males female , age ≥ 18 year ( ≥ 20 Japanese subject ) time consent . 2 . Have diagnosis atopic dermatitis ≥ 12 month . 3 . Have moderate severe atopic dermatitis consider inappropriate topical therapy adequately control topical therapy . 4 . Meet laboratory criterion define per protocol 5 . Females Childbearing Potential ( FCBP ) must negative pregnancy test Screening Baseline . Sexually active FCBP must use one approve contraceptive option require per protocol least 28 day last dose study medication 6 . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception least 28 day last dose study medication . 1 . Active tuberculosis ( TB ) history inadequately treated tuberculosis . 2 . Positive hepatitis B surface antigen hepatitis C antibody 3 . Pregnant breast feed 4 . History allergy component study medication . 5 . Active skin infection require systemic antimicrobial Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Atopic Eczema</keyword>
</DOC>